

Kyowa Hakko Kirin Co., Ltd.**Appendix to the Fiscal 2010 First Quarter Consolidated Financial Statements**

First quarter results for Fiscal 2010

(January 1, 2010 - March 31, 2010)

Index	Page
I. Consolidated Financial results	
1. Income	1
2. Results by segment	1
3. Other income	2
4. Extraordinary income/losses	2
5. R&D expenses	2
6. Capital expenditure	3
7. Depreciation expenses	3
8. Key indicators	3
II. Consolidated Subsidiaries and affiliates	4
III. Non-Consolidated Net sales by division	
1. Kyowa Hakko Kirin	5
2. Kyowa Hakko Bio	6
3. Kyowa Hakko Chemical	6
R&D Pipeline	7

This document was made as a supplement to the Kessan Tanshin (financial report) for the first quarter of Fiscal 2010, the three-month period from January 1, 2010 to March 31, 2010. This document contains forward-looking statements based on a number of assumptions and beliefs made by management in light of information currently available. For a variety of reasons, actual financial results may differ materially from the forecasts presented here.

I. Consolidated Financial Results

1. Trends in income

Millions of yen, rounded down

	(Ref: 2009) January 1 to March 31 results (A)	April 1, 2009 to December 31, 2009		(Ref: 2009) January 1 to December 31 results	January 1, 2010 to December 31, 2010				
		April 1 to June 30 results	April 1 to December 31 results		January 1 to March 31 results (B)	Change on January to March 2009		January to June forecast	January to December forecast
						Amount (B-A)	%		
Net sales	97,905	96,816	309,111	407,017	99,256	1,350	101%	200,000	400,000
Gross Profit	40,427	44,517	139,739	180,167	44,100	3,673	109%	--	--
Selling, general and administrative expenses	37,736	33,476	111,496	149,232	32,572	(5,163)	86%	--	--
Operating income (prior to amortization of goodwill)	5,090	13,367	35,221	40,311	13,853	8,763	272%	23,151	45,303
Operating income	2,690	11,041	28,243	30,934	11,527	8,836	428%	18,500	36,000
Other income	2,135	2,457	4,012	6,147	963	(1,171)		--	--
Other expenses	1,679	952	2,776	4,455	550	(1,128)		--	--
Recurring income	3,146	12,546	29,479	32,626	11,940	8,794	379%	19,000	37,500
Extraordinary income	6,075	--	27	6,102	--	(6,075)		--	--
Extraordinary expenses	7,568	1,734	8,878	16,447	577	(6,991)		--	--
Net income before income taxes	1,653	10,812	20,628	22,282	11,363	9,709	687%	17,500	36,000
Corporate, local and enterprise taxes	578	4,983	11,631	12,210	5,366	4,787		--	--
Income from minority interests	(168)	129	199	31	(57)	111		--	--
Net income	1,243	5,699	8,797	10,040	6,053	4,810	487%	9,500	20,000
EPS before goodwill amortization (#/share)	6.35	14.00	27.63	33.97	14.71			24.85	51.45

*As a result of the change in fiscal year end, the figures used for comparison above are those for the three month period from January 1 to March 31, 2009, which have been obtained by subtracting figures for the nine month period April 1, 2008 to December 31, 2008 from the figures for the twelve month period to March 2009. Also please note that figures for the Food segment are included in the reference figures for January 1 to March 31, 2009.

2. Trends in results by segment

(1) Results by operating segment

Millions of yen, rounded down

	(Ref: 2009) January 1 to March 31 results (A)	April 1, 2009 to December 31, 2009		(Ref: 2009) January 1 to December 31 results	January 1, 2010 to December 31, 2010				
		April 1 to June 30 results	April 1 to December 31 results		January 1 to March 31 results (B)	Change on January to March 2009		January to June forecast	January to December forecast
						Amount (B-A)	%		
Net sales	97,905	96,816	309,111	407,017	99,256	1,350	101%	200,000	400,000
Pharmaceuticals	49,111	52,211	158,273	207,384	49,674	562	101%	102,000	205,000
Bio-Chemicals	20,918	21,145	69,751	90,670	22,213	1,294	106%	44,000	84,000
Chemicals	11,881	15,034	52,326	64,208	30,281	18,399	255%	59,000	121,000
Food	9,633	--	--	9,633	--	(9,633)	--%	-	-
Other	14,231	14,195	49,500	63,731	2,493	(11,737)	18%	5,000	10,000
Total	105,776	102,586	329,851	435,628	104,662	(1,114)	99%	210,000	420,000
Eliminations	(7,871)	(5,770)	(20,740)	(28,611)	(5,406)	2,464	69%	(10,000)	(20,000)
Operating income	2,690	11,041	28,243	30,934	11,527	8,836	428%	18,500	36,000
<i>*Before goodwill amortization</i>	5,090	13,367	35,221	40,311	13,853	8,763	272%	23,151	45,303
Pharmaceuticals	5,169	11,570	26,657	31,826	9,678	4,509	187%	16,000	29,000
	7,326	13,727	33,129	40,455	11,835	4,509	162%	20,314	37,628
Bio-Chemicals	916	1,277	3,048	3,965	1,010	93	110%	2,000	4,000
	1,073	1,434	3,517	4,590	1,166	93	109%	2,312	4,625
Chemicals	(3,579)	(2,073)	(1,984)	(5,564)	674	4,254	--%	400	2,700
	(3,567)	(2,060)	(1,947)	(5,514)	686	4,254	--%	424	2,749
Food	87	--	--	87	--	(87)	--%	--	--
	161	--	--	161	--	(161)	--%	--	--
Other	34	184	400	434	82	48	242%	100	300
	34	184	400	434	82	48	242%	100	300
Total	2,628	10,960	28,122	30,750	11,446	8,818	436%	18,500	36,000
	5,027	13,285	35,100	40,127	13,772	8,745	274%	23,151	45,303
Eliminations	62	81	121	184	81	18	129%	--	--

Notes: 1. Figures representing amounts before goodwill amortization have been italicized.

2. Results of subsidiaries Miyako Kagaku Co., Ltd., and Kashiwagi Corporation, are reported under the Chemicals segment rather than the Other segment as of the January 1, 2010 to December 31, 2010 period.

(2) Overseas sales

Millions of yen, rounded down

	(Ref: 2009)		April 1, 2009 to December 31, 2009				(Ref: 2009)		January 1, 2010 to December 31, 2010	
	January 1 to March 31 results	Percentage of consolidated sales	April 1 to June 30 results	Percentage of consolidated sales	April 1 to December 31 results	Percentage of consolidated sales	January 1 to December 31 results	Percentage of consolidated sales	January 1 to March 31 results	Percentage of consolidated sales
Overseas sales	13,842	14.1%	18,444	19.1%	63,367	20.5%	77,209	19.0%	19,955	20.1%
America	3,821	3.9%	4,738	4.9%	16,849	5.5%	20,670	5.1%	5,162	5.2%
Europe	4,514	4.6%	5,996	6.2%	18,524	6.0%	23,038	5.7%	5,687	5.7%
Asia	5,294	5.4%	7,627	7.9%	27,415	8.9%	32,709	8.0%	8,991	9.1%
Other regions	213	0.2%	82	0.1%	578	0.2%	791	0.2%	113	0.1%
Total consolidated net sales	97,905	100.0%	96,816	100.0%	309,111	100.0%	407,017	100.0%	99,256	100.0%

3. Trends in other income

Millions of yen, rounded down

	(Ref: 2009) January 1 to March 31 results	April 1, 2009 to December 31, 2009		(Ref: 2009) January 1, 2009 to December 31, 2009 results	January 1 to December 31, 2010
		April 1 to June 30 results	April 1 to December 31 results		
Other income	2,135	2,457	4,012	6,147	963
Interest received	153	158	443	597	97
Dividend income	1,418	1,042	914	2,333	49
Foreign exchange gain	135	--	--	135	36
Income from equity method investments	215	743	1,558	1,774	337
Other	210	513	1,095	1,306	442
Other expenses	1,679	952	2,776	4,455	550
Interest expense	109	83	244	354	69
Foreign exchange loss	(555)	206	112	(443)	--
Loss from disposal of fixed assets	1,277	296	1,163	2,441	243
Other	847	365	1,255	2,103	237

4. Trends in extraordinary income / losses

Millions of yen, rounded down

	(Ref: 2009) January 1 to March 31 results	April 1, 2009 to December 31, 2009		(Ref: 2009) January 1, 2009 to December 31, 2009 results	January 1 to December 31, 2010
		April 1 to June 30 results	April 1 to December 31 results		
Extraordinary income	6,075	--	27	6,102	--
Gain on sale of fixed assets	--	--	27	27	--
Gain on sale of shares in affiliates	4,721	--	--	4,721	--
Gain of sale of investments in affiliates	1,354	--	--	1,354	--
Extraordinary losses	7,568	1,734	8,878	16,447	577
Loss on revision to retirement benefit system	--	--	--	--	577
Extraordinary depreciation of fixed assets	--	--	3,299	3,299	--
Asset impairment losses	3,793	--	2,671	6,464	--
Loss from change in equity affiliates*	--	1,379	1,379	1,379	--
Loss from sale of investment securities	--	--	991	991	--
Loss from revaluation of investment securities	1,367	354	537	1,905	--
Integration-related expenses	1,429	--	--	1,429	--
Other	977	--	--	977	--

5. Trends in R&D expenses

Billions of yen, rounded down

	(Ref: 2009) January 1 to March 31 results	April 1, 2009 to December 31, 2009		(Ref: 2009) January 1, 2009 to December 31, 2009 results	January 1 to December 31, 2010		
		April 1 to June 30 results	April 1 to December 31 results		January 1 to March 31 results	January 1 to June 30 forecast	January 1 to December 31 forecast
R&D (Consolidated)	11.4	9.3	34.9	46.4	9.1	22.2	46.4
R&D to net sales ratio	11.7%	9.7%	11.3%	11.4%	9.2%	11.1%	11.6%
Pharmaceuticals	10.0	8.2	31.6	41.6	8.1	19.7	41.5
(R&D to net sales ratio)	20.5%	15.8%	20.0%	20.1%	16.4%	19.4%	20.3%
Bio-Chemicals	0.8	0.8	2.5	3.4	0.7	1.9	3.7
Chemicals	0.2	0.2	0.7	1.0	0.2	0.5	1.0
Food	0.2	--	--	0.2	--	--	--
Other	0.0	0.0	0.0	0.0	--	--	--

6. Trends in capital expenditure

Billions of yen, rounded down

	(Ref: 2009) January 1 to March 31 results	April 1, 2009 to December 31, 2009		(Ref: 2009) January 1, 2009 to December 31, 2009 results	January 1 to December 31, 2010		
		April 1 to June 30 results	April 1 to December 31 results		January 1 to March 31 results	January 1 to June 30 forecast	January 1 to December 31 forecast
Capital expenditure (Consolidated)	5.5	8.4	24.0	29.6	5.5	14.4	27.8
Pharmaceuticals	4.0	5.3	15.4	19.5	4.3	7.8	15.6
Bio-Chemicals	1.4	1.7	4.9	6.4	0.9	4.5	9.6
Chemicals	1.3	1.4	3.5	4.9	0.2	2.0	2.5
Food	0.0	--	--	0.0	--	--	--
Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Eliminations	(1.5)	--	(0.0)	(1.5)	--	--	--

7. Trends in depreciation expenses

Billions of yen, rounded down

	(Ref: 2009) January 1 to March 31 results	April 1, 2009 to December 31, 2009		(Ref: 2009) January 1, 2009 to December 31, 2009 results	January 1 to December 31, 2010		
		April 1 to June 30 results	April 1 to December 31 results		January 1 to March 31 results	January 1 to June 30 forecast	January 1 to December 31 forecast
Depreciation expenses (Consolidated)	4.4	4.0	17.0	21.4	4.2	9.5	22.1
Pharmaceuticals	1.7	1.7	9.2	10.9	1.9	4.5	11.5
Bio-Chemicals	1.2	1.2	4.3	5.5	1.2	2.7	5.8
Chemicals	1.1	0.9	3.3	4.4	1.0	2.2	4.7
Food	0.2	--	--	0.2	--	--	--
Other	0.0	0.0	0.1	0.1	0.0	0.0	0.0
Eliminations	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	--	--

8. Trends in key indicators

(1) Exchange rate

	(Ref: 2009) January 1 to March 31 results	April 1, 2009 to December 31, 2009		(Ref: 2009) January 1, 2009 to December 31, 2009 results	January 1 to December 31, 2010		
		April 1 to June 30 results	April 1 to December 31 results		January 1 to March 31 results	January 1 to June 30 forecast	January 1 to December 31 forecast
US Dollar (¥/US\$)	94	97	94	94	91	91	91
Euro (¥/Euro)	122	133	133	130	126	129	131

(2) Operating indicators (Consolidated)

	April 1, 2009 to December 31, 2009		January 1 to December 31, 2010
	April 1 to June 30 results	April 1 to December 31 results	January 1 to December 31
(prior to amortization of goodwill)	14.00	27.63	14.71
Net income per share (yen)	9.94	15.41	10.63
Operating income to sales ratio (%)	11.4%	9.1%	11.6%
Total assets (million yen)	708,477	695,268	684,773
Net assets (million yen)	543,439	540,343	542,837
Equity ratio (%)	76.1%	77.1%	78.7%
Net assets per share (yen)	944.80	940.79	946.72
Number of staff at end of term	7,494	7,436	7,362

II. Subsidiaries and affiliates

(As of March 31, 2010)

Segment	Type	Company name	Percentage owned (direct and indirect)	Principal business
Pharmaceuticals	Consolidated subsidiary	Kyowa Medex Co., Ltd.	100.0%	Manufacture and sale of diagnostic reagents
		Kirin Kunpeng (China) Bio- Pharmaceutical Co., Ltd.	70.0%	Manufacture and sale of pharmaceuticals (China)
		Kyowa Medical Promotion Co., Ltd.	100.0%	Sales promotion of pharmaceuticals
		Kyowa Hakko Kirin America, Inc.	100.0%	Holding company for administration and management of US subsidiaries (US)
		BioWa, Inc.	100.0%	Out-licensing and promotion of anti-body technology (US)
		Kyowa Hakko Kirin Pharma, Inc.	100.0%	Development of outsourced pharmaceutical products
		Kyowa Hakko Kirin California, Inc.	100.0%	Generate new candidate substances and develop pharmaceuticals (US)
		Hematech, Inc.	100.0%	Technology research for manufacture of therapeutic antibody (US)
		Hematech-GAC Venture, LLC	51.0%	Technology research for manufacture of therapeutic antibody (US)
		Kyowa Italiana Farmaceutici S.R.L.	100.0%	Sales of pharmaceuticals (Italy)
		Jeil-Kirin Pharmaceutical Inc.	90.0%	Sales of pharmaceuticals (Korea)
		Kyowa Kirin Pharmaceuticals (Taiwan) Co., Ltd.	100.0%	Sales of pharmaceuticals (Taiwan)
		Kyowa Hakko Kirin (Hong Kong) Co., Ltd.	100.0%	Sales of pharmaceuticals (Hong Kong)
		Kyowa Hakko Kirin (Singapore) Pte. Ltd.	100.0%	Sales of pharmaceuticals (Singapore)
Bio-Chemicals	Consolidated subsidiary	Kyowa Hakko Bio Co., Ltd.	100.0%	Manufacture and sale of pharmaceutical and industrial raw materials, and health care products
		Daiichi Fine Chemical Co., Ltd.	100.0%	Manufacture and sale of active pharmaceutical ingredients and pharmaceutical intermediates
		Biokyowa Inc.	100.0%	Manufacture and sale of amino acids (US)
		Shanghai Kyowa Amino Acid Co., Ltd.	70.0%	Manufacture and sale of amino acids (China)
		Kyowa Hakko U.S.A., Inc.	100.0%	Sale and import/export of fine chemicals including amino acids (US)
		Kyowa Hakko Europe GMBH	100.0%	Sale and import/export of fine chemicals including amino acids (Germany)
		Kyowa Italiana Farmaceutici S.R.L.	100.0%	Sale and import/export of fine chemicals including amino acids (Italy)
		Kyowa Hakko (H.K.) Co., Ltd.	100.0%	Sale and import/export of fine chemicals including amino acids (Hong Kong)
		Kyowa Hakko Bio Singapore Pte. Ltd. (*1)	100.0%	Sale and import/export of fine chemicals including amino acids (Singapore)
		Kyowa Hakko Bio U.S. Holdings, Inc.	100.0%	Holding company for administration and management of US subsidiaries (US)
		Kyowa Wellness Co., Ltd.	100.0%	Sale of healthcare products
		Shinwa Pharmaceutical Co., Ltd.	100.0%	Sale of herbal medicines and health foods
Kyowa Engineering Co., Ltd.	100.0%	Design and installation of plant facilities and equipment		
Chemicals	Consolidated subsidiary	Kyowa Hakko Chemical Co., Ltd.	100.0%	Manufacture and sale of chemicals
		Miyako Kagaku Co., Ltd.	71.1%	Wholesale sales of pharmaceutical raw materials, chemicals, foods, etc.
		Kashiwagi Corporation	91.0%	Wholesale sales of chemicals, food, etc.
	Affiliate accounted for by the equity method	J-PLUS Co., Ltd.	50.0%	Manufacture and sale of plasticizers
Kurogane Kasei Co., Ltd.	40.0%	Manufacture and sale of plasticizers, fine chemicals, etc.		
Other	Consolidated subsidiary	Chiyoda Kaihatsu Co., Ltd.	100.0%	Transportation, insurance, wholesale sales of food, etc.
	Affiliate accounted for by the equity method	Japan Synthetic Alcohol Co., Ltd.	33.3%	Manufacture and sale of industrial use alcohol
		Kirin Kyowa Foods Company, Limited	35.0%	Manufacture and sale of seasonings, confectionery and bread products
		Kyowa F.D. Foods Co., Ltd.	35.0%	Manufacture and sale of freeze-dried foods
		Kirin Ohland Foods Co., Ltd.	35.0%	Manufacture and sale of bakery products, etc.
		Kyowa HiFoods Co. Ltd.	35.0%	Import and sale of foods, etc.
		Aji-Nihon Co., Ltd.	16.2%	Manufacture and sale of foods and seasonings, etc.
Zenmi Foods Inc.	17.5%	Manufacture and sale of seasonings		

Notes: 1. Changes to the scope of consolidation

Newly consolidated: Two companies: Kyowa Italiana Farmaceutici S.R.L. and Kyowa Hakko Bio Singapore Pte. Ltd.

2. As of the January 1, 2010 to December 31, 2010 period Miyako Kagaku Co., Ltd., and Kashiwagi Corporation are reported under the Chemicals segment rather than the Other segment

III. Net sales by division (Items and main products)

1. Kyowa Hakko Kirin

Billions of yen, rounded down

Pharmaceuticals division (non-consolidated)	(Ref: 2009) January 1 to March 31 results	April 1, 2009 to December 31, 2009		(Ref: 2009) January 1, 2009 to December 31, 2009 results	January 1 to December 31, 2010		
		April 1 to June 30 results	April 1 to December 31 results		January 1 to March 31 results	January 1 to June 30 forecast	January 1 to December 31 forecast
Pharmaceutical division total	43.7	47.8	143.9	187.6	45.3	93.9	188.6
Central nervous system agents							
<i>Depakene</i>	2.4	2.8	8.8	11.2	2.3	5.3	11.0
<i>Topina</i>	0.2	0.3	1.2	1.5	0.4	0.9	1.9
Sensory organ agents							
<i>Patanol</i>	4.4	0.8	3.0	7.4	3.5	5.3	7.9
Circulatory organ agents							
<i>Coniel</i>	5.0	6.0	18.3	23.3	4.8	10.6	21.3
<i>Inovan / Pre Dopa</i>	0.8	0.9	2.7	3.5	0.7	1.6	3.3
<i>Coversyl</i>	1.0	1.2	3.7	4.8	0.9	2.2	4.4
Digestive organ agents							
<i>Nauzelin</i>	1.2	1.2	3.8	5.1	1.3	2.5	5.3
<i>Other agent affecting metabolism</i>							
<i>Nesp/Espo</i>	9.2	12.8	39.6	48.9	10.3	25.2	49.7
<i>Regpara</i>	1.2	1.6	5.5	6.8	1.9	3.6	7.3
<i>Agents relating to blood and body fluids</i>							
<i>Gran/Neu-up*2</i>	3.2	4.4	13.8	17.0	3.3	7.0	15.1
Anticancer agents							
<i>Farmorubicin / Adriacin</i>	1.4	1.7	4.9	6.4	1.1	2.8	5.5
<i>5 – FU (all types)</i>	0.8	0.9	2.9	3.7	0.7	1.4	2.7
<i>Navelbine</i>	0.6	0.8	2.2	2.9	0.5	1.3	2.6
Antiallergic agents							
<i>Allelock</i>	9.3	5.8	17.3	26.7	8.2	14.2	26.0
<i>Celtect</i>	1.0	0.8	2.3	3.3	0.7	1.5	2.7
Exports and Technology Out-Licensing	2.8	5.5	15.1	18.0	5.5	12.2	22.6

Notes 1: Results based on settlement price on a shipment basis. Forecasts are based on an actual consumption basis.

2: As of March 1, 2010, manufacturing, sales and other rights for Neu-up will be transferred to Yakult Honsha. Therefore, Gran/Neu-up figures after March 31, 2010 include only sales figures for Gran.

2. Kyowa Hakko Bio

Billions of yen, rounded down

Bio-Chemicals division (non-consolidated)	(Ref: 2009) January 1 to March 31 results	April 1, 2009 to December 31, 2009		(Ref: 2009) January 1, 2009 to December 31, 2009 results	January 1 to December 31, 2010		
		April 1 to June 30 results	April 1 to December 31 results		January 1 to March 31 results	January 1 to June 30 forecast	January 1 to December 31 forecast
Bio-Chemical division total	13.0	13.6	42.3	55.4	14.8	27.7	52.2
Pharmaceuticals / Industrial raw materials							
Amino acids	4.3	4.9	14.8	19.1	5.5	10.0	19.5
Nucleic acids and vitamins	1.0	0.9	3.5	4.5	1.3	2.4	4.9
Health care products	1.9	2.1	6.5	8.4	2.3	4.4	9.0
Agrochemicals, livestock and fisheries products	1.0	0.8	2.1	3.2	1.0	1.5	1.9
Alcohol	2.0	2.4	7.8	9.8	2.0	4.7	7.6

Notes 1. As of April 1, 2010 the domestic livestock and fisheries industry product sales operations of Kyowa Hakko Bio Co., Ltd. have been transferred to Aska Pharmaceuticals Co., Ltd.

2. On July 1, 2010, the Kyowa Hakko Bio Co., Ltd. alcohol business is scheduled to be transferred to Daiichi Alcohol Co. Ltd., a joint venture with Mercian Corporation (planned investment ratio: 35%).

3. Kyowa Hakko Chemical

Billions of yen, rounded down

Chemicals division (non-consolidated)	(Ref: 2009) January 1 to March 31 results	April 1, 2009 to December 31, 2009		(Ref: 2009) January 1, 2009 to December 31, 2009 results	January 1 to December 31, 2010		
		April 1 to June 30 results	April 1 to December 31 results		January 1 to March 31 results	January 1 to June 30 forecast	January 1 to December 31 forecast
Chemicals division total	11.8	14.9	52.3	64.2	19.3	38.3	80.3
Solvents	4.6	4.1	22.6	27.2	7.4	16.9	35.1
Raw materials for plasticizers	3.5	6.8	16.3	19.8	6.3	11.5	24.8
Specialty chemicals	3.1	3.1	11.3	14.5	4.6	8.8	18.2

R&D PIPELINE

Phase II, Phase III

Apr 28th 2010

Category	Code Name Product Name	Stage		Indication	Formulation	In-house OR Licensed	Remarks
		Japan	Other countries				
Cancer/Hematology	KW-0761	Phase II	Phase I / II a in USA	Cancer (Hematologic tumor)	Injection	Developed In-house	Humanized monoclonal antibody KW-0761 was outlicensed to Amgen Inc. in March 2008, with an exclusive right to develop and commercialize KW-0761 worldwide for all indications other than cancer except in Japan, Korea, China and Taiwan.
	KRN 321 NESP	Filed Nov/2008		☆ Chemotherapy induced anemia	Injection	Kirin-Amgen	Long-acting erythropoiesis stimulating protein Launched in Japan in July 2007 for anemia of CKD patients on dialysis.
	AMG 531	Filed Mar/2010		Immune thrombocytopenic purpura	Injection	Kirin-Amgen	Thrombopoiesis stimulating protein
	KW-2246	Filed Feb/2010		Cancer pain	Sublingual tablet	Licensed from Orexo	
	KRN 125	Phase II		Neutropenia	Injection	Kirin-Amgen	Long-acting G-CSF
Kidney	KRN 321 NESP	Approved Apr/2010		☆ Anemia (not on dialysis)	Injection	Kirin-Amgen	Long-acting erythropoiesis stimulating protein Launched in Japan in July 2007 for anemia of CKD patients on dialysis.
			Phase II in China	☆ Anemia (on dialysis)			
Immunology/Allergy	KW-4679 ALLELOCK		Filed in China Jul/2008	Allergy	Oral	Developed In-house	Launched in Japan
CNS	KW-6002	Phase III	Filed in USA Apr/2007	Parkinson's disease	Oral	Developed In-house	
	KW-6500	Phase III		Parkinson's disease	Injection	Licensed from Britannia Pharma.	

Phase I

Category	Code Name Product Name	Stage		Indication	Formulation	In-house OR Licensed	Remarks
		Japan	Other countries				
Cancer/Hematology	KW-2450		Phase I in USA	Cancer	Oral	Developed In-house	
	KRN 654	Phase I/II		Essential thrombocythemia	Oral	Licensed from Shire.	
	KW-2449		Phase I / II a in USA	Cancer	Oral	Developed In-house	
	KW-2478		Phase I in Europe	Cancer	Injection	Developed In-house	
	ARQ 197	Phase I		Cancer	Oral	Licensed from ArQule.	
	KRN 330		Phase I / II a in USA	Cancer	Injection	Developed In-house	Fully human monoclonal antibody
	BIW-8962		Phase I / II a in USA	Cancer	Injection	Developed In-house	Humanized monoclonal antibody
	KRN 951	Phase I		Cancer	Oral	Developed In-house	
Immunology/Allergy	KHK 4563	Phase I		Asthma	Injection	Developed In-house	Humanized monoclonal antibody Being developed by MedImmune as MEDI-563 worldwide except in Japan and other Asian countries
	Z-206 ASACOL	Phase I		Inflammatory bowel disease (Crohn's disease)	Oral <small>(pH depend controlled-release formulation)</small>	Licensed from Zeria Pharma.	Jointly developed with Zeria Pharma (Additional Phase I)
	ASKP 1240		Phase I	Organ Transplant Rejection	Injection	Developed with Astellas.	Fully human monoclonal antibody
Other	KW-3357	Phase I	Phase I in Europe	Disseminated intravascular coagulation, Congenital antithrombin deficiency	Injection	Developed In-house	Recombinant antithrombin product
	KRN23		Phase I in USA	X-linked Hypophosphatemic rickets/osteomalacia (XLH)	Injection	Developed In-house	Fully human monoclonal antibody

(Note)
In Philippines, an NDA of Filgrastim(G-CSF) has been filed for neutropenia.
In Thailand, Singapore, Malaysia, and Philippines, NESP(Long-acting erythropoiesis stimulating protein) has been filed. In Korea, Taiwan, and Hong Kong, NESP was approved.
In Korea and Taiwan REGPARA (Calcimimetic agent) has been filed. In Hong Kong (Macau), REGPARA was approved.

Updated since January 29, 2010 (Area, Stage, Filed, Approved, Launched etc.)

☆ New indication

Discontinued

Category	Code Name Product Name	Stage		Indication	Formulation	In-house OR Licensed	Reason
		Japan	Other countries				
Kidney	PE94 PHOSBLOCK (RENAGEL)		Filed in China Jun/2008	Hyperphosphatemia	Oral	Licensed from Chugai	Approval is not expected in the current NDA package